Lusaris Therapeutics develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders.
Lusaris Therapeutics has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in November 2022.
Lusaris Therapeutics's investors include RA Capital Management, Venrock Healthcare Capital Partners, Deep Track Capital, Boxer Capital.
Lusaris Therapeutics is headquartered in Boston, United States.
Lusaris Therapeutics develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders.
Lusaris Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lusaris Therapeutics — Funding & Investors." VCBacked, November 2, 2022, https://www.vcbacked.co/company/lusaris-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Lusaris Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/lusaris-therapeutics
{{cite web |title=Lusaris Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lusaris-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated